Canadian Task Force on Preventive Health Care

Selected References

Preventive health care, 2001 update: Use of varicella vaccine in healthy populations

Prepared  by S.A. Skull, MBBS, FRACP, FAFPHM, MAppEpid, E.E.L. Wang, MCDM, FRCP(C), with the Canadian Task Force on Preventive Health Care

These recommendations were finalized by the Task Force in June 1999.

  1. Ross A. Modification of chicken pox in family contacts by administration of gamma globulin. Lancet 1962; 267:369-76.
  2. Bernstein HH, Rothstein EP, Watson BM, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993; 92:833-7.
  3. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practises (ACIP). MMWR 1996; 45:1-37.
  4. American Academy of Pediatrics. Red Book: Report of the Committee on Infectious Diseases.  Summaries of infectious diseases. Varicella-zoster infections. In: Peter G, ed. Elk Grove Village, Illinois: American Academy of Pediatrics, 1997:573-85.
  5. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Lond 1965; 58:9-20.
  6. Centers for Disease Control and Prevention. Evaluation of varicella reporting to the National Notifiable Disease Surveillance System - United States, 1972-1997. MMWR 1999; 48:55-8.
  7. van Loon F, Markovitz L, McQuillan G. Varicella seroprevalence in U.S. population.  In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans).  Washington, DC: American Society for Microbiology.  1993:Abstract 1311.
  8. Ooi PL, Goh KT, Doraisingham S, Ling AE. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 1992; 23:22-5.
  9. Longfield JN, Winn RE, Gibson RL, Juchau SV, Hoffman PV. Varicella outbreak in army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. Arch Intern Med 1990; 150:970-3.
  10. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 1996; 10:571-81.
  11. Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. Journal of Infectious Diseases 1998; 178 Suppl 1:S52-4.
  12. Miller E, Vurdien J, Farrington P. Shift in age of chickenpox [letter]. Lancet 1993; 341:308-9.
  13. Gray G, Palinkas L, Kelley P. Increasing incidence of varicella hospitalizations in the United States army and navy personnel: are today's teenagers more suceptible? Pediatrics 1990; 86:867-73.
  14. Centers for Disease Control and Prevention. Varicella-related deaths among children - United States, 1997. MMWR 1998; 47:365-358.
  15. Gershon A, LaRussa P. Varicella vaccine. Pediatr Infect Dis J 1998; 17:248-9.
  16. Centers for Disease Control and Prevention. National, State, and urban area vaccination coverage levels among children aged 19-35 months - United States, 1997. MMWR 1998; 47:547-54.
  17. Preblud SR. Varicella: complications and costs. Pediatrics 1986; 78 (Suppl):728-35.
  18. Choo PW, Donahue JG, Manson JE. The epidemiology of varicella and its complications. J Infect Dis 1995; 172:706-12.
  19. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. Journal of Pediatrics 1997; 130:759-65.
  20. Davies HD, McGeer A, Schwartz B, et al. Invasive Group A Streptococcal Infections in Ontario, Canada. NEJM 1996; 335:547-54.
  21. Fleisher GW, Henry W, McSorley M, Arbeter A, Plotkin S. Life-threatening complications of varicella. AJDC 1981; 135:896-9.
  22. Sullivan-Bolyai JZ, Yin EK, Cox P, et al. Impact of chickenpox on households of healthy children. Pediatr Infect Dis J 1987; 6:33-5.
  23. Lieu T, Black S, Rieser N, Ray P, Lewis E, Shinefield H. The cost of childhood chickenpox: parents' perspective. Pediatr Infect Dis J 1994; 13:173-7.
  24. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78(Suppl):723-7.
  25. Arbeter AM. Clinical trials of varicella vaccine in healthy adolescents and adults. Infect Dis Clin North Am 1996; 10:609-15.
  26. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.
  27. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548-51.
  28. Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901-5.
  29. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 1989; 2:371-3.
  30. Law B, Fitzsimon C, Ford-Jones L, McCormick J, Riviere M. Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT). Pediatrics 1999; 104:7-14.
  31. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vacination program for U.S. children. JAMA 1994; 271:375-81.
  32. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics 1999; 104:1-6.
  33. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-90.
  34. Fanget B, Francon A. A varicella vaccine stable at 5oC. Dev Biol Stand 1996; 87:167-71.
  35. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 1996; 174 (Suppl 3):S330-4.
  36. Tan AY, Connett CJ, Connet GJ, et al. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. Eur J Pediatr 1996; 155:706-11.
  37. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am 1996; 10:595-608.
  38. National Advisory Committee on Immunization (NACI). Statement on recommended use of varicella virus vaccine. Canada Communicable Disease Report 1999; 25(ACS-1):1-16.
  39. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140:81-104.
  40. Brunell P. Brunell's brush off. Pediatrics 1977; 59:954.
  41. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E, and other members of the Canadian Task Force on the Periodic Health Examination. Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 1990; 43:891-905.
  42. Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventive Health Care. Ottawa: CCG, 1994.
  43. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310:1409-15.
  44. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9:643-7.
  45. Rothstein E, Bernstein H, Associates PP, Ngai A, Cho I, White C. Dose titration study of live attenuated varicella vaccine in healthy children. J Infect Dis 1997; 175:444-7.
  46. Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two  injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996; 15:49-54.
  47. Johnson C, Stancin T, Fattlar D, Rome L, Kumar M. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997; 100:761-6.
  48. Takayama N, Minamitani M, Takayama M. High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jap 1997; 39:663-8.
  49. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985; 75:667-71.
  50. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996; 174 (Suppl 3):S310-3.
  51. Watson B, Piercy S, Plotkin S, Starr S. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91:17-22.
  52. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87:604-10.
  53. White C, Kuter B, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19-23.
  54. Johnson C, Rome L, Stancin T, Kumar M. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989; 84:418-21.
  55. Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M. Clinical trials of the Oka strain of live attenuated varicella vaccine on healthy children. Biken J 1984; 27:39-42.
  56. Asano Y, Takahashi M. Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics 1977; 60:810-14.
  57. Ndumbe PM, Cradock-Watson JE, MacQueen S, et al. Immunisation of nurses with a live varicella vaccine. Lancet 1985; i:1144-47.
  58. Gershon A, Steinberg S, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132-7.
  59. Gershon A, Steinberg S, Gelb L, National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine use in immunocompromised  children and adults. Pediatrics 1986; 78 (Suppl):757-62.
  60. Kuter B, Ngai A, Patterson C, Staehle B, Cho I, Matthews H. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Vaccine 1995; 13:967-72.
  61. Watson B, Laufer D, Kuter B, Staehle B, White C, Starr S. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMRiiV) in healthy children. J Infect Dis 1996; 173:731-4.
  62. White C, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 1997; 24:925-31.
  63. Brunell P, Novelli V, Lipton S, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988; 81:779-84.
  64. Arbeter A, Baker L, Starr S, Plotkin S. The combination measles,mumps, rubella and varicella vaccine in healthy children. Develop Biol Standard 1986; 65:89-93.
  65. Arbeter A, Baker L, Starr S, Levine B, Books E, Plotkin S. Combination measles, mumps, rubella, and varicella vaccine. Pediatrics 1986; 76 (Suppl):742-7.
  66. Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis 1998; 178 (Suppl 1):S99-103.
  67. Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HHJ. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr 1989; 114:37-44.
  68. Levin M, Murray M, Rotbart H, Zerbe G, White C, Hayward A. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166:235-9.
  69. Ramikissoon A, Coovadia H, Jugnundan P, Haffejee I, Meurice F, Vandevoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9 - 24 months. S Afr Med J 1995; 85:1295-8.
  70. Asano Y, Yazaki T, Ito S, Isomura S, Takahashi M. Contact infection from live varicella vaccine recipients. Lancet 1976; 1:965.
  71. Diaz PS, Au D, Smith S. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87:166-70.
  72. Salzman M, Sharrar R, Steinberg S, La Russa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151-4.
  73. La Russa P, Steinberg S, Meurice F, Gershon A. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis 1997; 176:1072-5.
  74. Kacica M, Connelly B, Myers M. Communicable varicella in a health care worker 21 months following successful vaccination with live attenuated varicella vaccine. Abstracts of the 1988 ICAAC 1988:#727.
  75. Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. Unintentional administration of varicella virus vaccine--United States, 1996. JAMA 1996; 276:1792.
  76. Horiuchi K. Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982. Biken J 1984; 27:37-8.
  77. Asano Y, Nagai T, Miyata T, Yazaki T. Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka). Biken J 1984; 27:123-8.
  78. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94:524-6.
  79. Plotkin S, Starr S. Zoster in normal children after varicella vaccine. J Infect Dis 1989; 159:1000-1.
  80. White CJ. Letters to the editor. Pediatrics 1992; 89:353-4.
  81. Guess HA, Broughton DD, Melton LJI, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985; 76:512-7.
  82. Centers for Disease Control and Prevention. Prevention of varicella updated.  Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48:1-5.
  83. Hammerschlag MR, Gershon A, Steinberg S, Clarke L, Gelb L. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989; 160:535-7.
  84. Levin M, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: durations of booster effect. J Infect Dis 1998; 178 (Suppl 1):S109-12.
  85. Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 1985; 61 (Suppl 4):61-7.
  86. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986; 77:53-6.
  87. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35-9.
  88. Fairley CK, Miller E. Varicella-zoster virus epidemiology - A changing scene? J Infect Dis 1996; 174 (Suppl 3):S314-9.
  89. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: The influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 1992; 108:513-28.
  90. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune reponses in the elderly by boosting with varicella vaccine. J Infect Dis 1984; 149:647.
  91. Preblud S, Orenstein W, Koplan J, Bart K, Hinman A. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985; 61 (Suppl 4):17-22.
  92. Huse D, Meissner C, Lacey M, Oster G. Childhood vaccination against chickenpox: An analysis of benefits and costs. J Pediatr 1994; 124:869-74.
  93. Beutels P, CG T, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 (Suppl 3):S335-41.
  94. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 1995; 95:632-8.
  95. Lieu TA, Black SB, Takahashi H, et al. Varicella serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J 1998; 17:120-5.
  96. Gray A, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 1997; 119:209-20.
  97. Anonymous. Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics; Committee on Infectious Diseases. Pediatrics 1995; 95:791-6.

Link to Recommendation Statement of this review

Link to Full Technical Report (in pdf)

Link to Structured Abstract of this review

Link to Summary Table of Recommendations of this review

Top of Page

CTFPHC Home Page

Reprinted in modified format by the Canadian Task Force on Preventive Health Care
Original Copyright © 2000 Canadian Medical Association.
For any technical issues please contact: webmaster@ctfphc.org
Last modified: April 08, 2003